Medical Research, Diagnostic Substances & Life Science Tools

April 21, 2017

Companies covered: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG), Soligenix, Inc. (NASDAQ:SNGX), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), ContraVir Pharmaceuticals (NASDAQ:CTRV), Cancer Genetics, Inc. (NASDAQ:CGIX), Advanced Accelerator Applications S.A. (NASDAQ:AAAP), BeiGene Ltd (ADR) (NASDAQ:BGNE), National Health Investors, Inc. (NYSE:NHI), GlycoMimetics, Inc. (NASDAQ:GLYC), Daxor Corporation (NYSEMKT:DXR), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), United Therapeutics Corporation (NASDAQ:UTHR), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Cellectis S.A. (NASDAQ:CLLS), Syndax Pharmaceuticals Inc (NASDAQ:SNDX), Pfizer, Inc. (NYSE:PFE), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), Gilead Sciences, Inc. (NASDAQ:GILD), Intel Corporation (NASDAQ:INTC), Xerox Corporation (NYSE:XRX), Microsoft Corporation (NASDAQ:MSFT), Apple Inc. (NASDAQ:AAPL), Astrazeneca PLC (NYSE:AZN), Galenica AG (VTX:VIFN), Loxo Oncology, Inc. (NASDAQ:LOXO), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Sanofi (NYSE:SNY), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), Puma Biotechnology Inc (NYSE:PBYI), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Versartis, Inc. (NASDAQ:VSAR), Intra-Cellular Therapies Inc. (NASDAQ:ITCI), Sage Therapeutics, Inc. (NASDAQ:SAGE), Cempra, Inc. (NASDAQ:CEMP), Achaogen, Inc. (NASDAQ:AKAO), Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), Otonomy, Inc. (NASDAQ:OTIC), Spark Therapeutics, Inc. (NASDAQ:ONCE), Galapagos NV (NASDAQ:GLPG), bluebird bio, Inc. (NASDAQ:BLUE), Nektar Therapeutics (NASDAQ:NKTR), Clovis Oncology, Inc. (NASDAQ:CLVS), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Bristol-Myers Squibb Company (NYSE:BMY), TESARO, Inc. (NASDAQ:TSRO), uniQure N.V. (NASDAQ:QURE), Intrexon Corporation (NYSE:XON), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Fibrocell Science Inc (NASDAQ:FCSC), AquaBounty Technologies, Inc. (NASDAQ:AQB), Thermo Fisher Scientific Inc (NYSE:TMO), Waters Corporation (NYSE:WAT), Mettler-Toledo International, Inc. (NYSE:MTD), Novartis AG (NYSE:NVS), Merck & Company, Inc. (NYSE:MRK), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Illumina, Inc. (NASDAQ:ILMN), Physicians Realty Trust (NYSE:DOC), Global Medical REIT Inc (NYSE:GMRE), Healthcare Trust of America, Inc. (NYSE:HTA), ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ), Allergan, Inc. (NYSE:AGN), Hologic, Inc. (NASDAQ:HOLX), Edwards Lifesciences Corporation (NYSE:EW), Medtronic, Inc. (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Abbott Laboratories (NYSE:ABT), DexCom, Inc. (NASDAQ:DXCM), Insulet Corporation (NASDAQ:PODD), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Intuitive Surgical, Inc. (NASDAQ:ISRG), Cynosure, Inc. (NASDAQ:CYNO)

Buy ($175)

Pin It on Pinterest

Share This